Literature DB >> 23299379

Passive immunotherapy for Alzheimer's disease: what have we learned, and where are we headed?

P S Aisen, B Vellas.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23299379     DOI： 10.1007/s12603-013-0001-3

Source DB:  PubMed          Journal:  J Nutr Health Aging        ISSN： 1279-7707            Impact factor:   4.075


× No keyword cloud information.
  12 in total

Review 1.  Testing the right target and right drug at the right stage.

Authors:  Reisa A Sperling; Clifford R Jack; Paul S Aisen
Journal:  Sci Transl Med       Date:  2011-11-30       Impact factor: 17.956

2.  Colombia at the centre of preclinical AD research.

Authors: 
Journal:  Lancet Neurol       Date:  2012-07       Impact factor: 44.182

3.  Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab.

Authors:  Susanne Ostrowitzki; Dennis Deptula; Lennart Thurfjell; Frederik Barkhof; Bernd Bohrmann; David J Brooks; William E Klunk; Elizabeth Ashford; Kisook Yoo; Zhi-Xin Xu; Hansruedi Loetscher; Luca Santarelli
Journal:  Arch Neurol       Date:  2011-10-10

4.  11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study.

Authors:  Juha O Rinne; David J Brooks; Martin N Rossor; Nick C Fox; Roger Bullock; William E Klunk; Chester A Mathis; Kaj Blennow; Jerome Barakos; Aren A Okello; Sofia Rodriguez Martinez de Liano; Enchi Liu; Martin Koller; Keith M Gregg; Dale Schenk; Ronald Black; Michael Grundman
Journal:  Lancet Neurol       Date:  2010-02-26       Impact factor: 44.182

5.  An effector-reduced anti-β-amyloid (Aβ) antibody with unique aβ binding properties promotes neuroprotection and glial engulfment of Aβ.

Authors:  Oskar Adolfsson; Maria Pihlgren; Nicolas Toni; Yvan Varisco; Anna Lucia Buccarello; Katia Antoniello; Sophie Lohmann; Kasia Piorkowska; Valerie Gafner; Jasvinder K Atwal; Janice Maloney; Mark Chen; Alvin Gogineni; Robby M Weimer; Deborah L Mortensen; Michel Friesenhahn; Carole Ho; Robert Paul; Andrea Pfeifer; Andreas Muhs; Ryan J Watts
Journal:  J Neurosci       Date:  2012-07-11       Impact factor: 6.167

6.  Alzheimer's disease therapeutic trials: EU/US Task Force report on recruitment, retention, and methodology.

Authors:  B Vellas; H Hampel; M E Rougé-Bugat; M Grundman; S Andrieu; S Abu-Shakra; R Bateman; R Berman; R Black; M Carrillo; M Donohue; M Mintun; J Morris; R Petersen; R G Thomas; J Suhy; L Schneider; L Seely; P Tariot; J Touchon; M Weiner; C Sampaio; P Aisen
Journal:  J Nutr Health Aging       Date:  2012-04       Impact factor: 4.075

7.  Safety and biomarker effects of solanezumab in patients with Alzheimer's disease.

Authors:  Martin Farlow; Steven E Arnold; Christopher H van Dyck; Paul S Aisen; B Joy Snider; Anton P Porsteinsson; Stuart Friedrich; Robert A Dean; Celedon Gonzales; Gopalan Sethuraman; Ronald B DeMattos; Richard Mohs; Steven M Paul; Eric R Siemers
Journal:  Alzheimers Dement       Date:  2012-06-05       Impact factor: 21.566

8.  Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice.

Authors:  K Hsiao; P Chapman; S Nilsen; C Eckman; Y Harigaya; S Younkin; F Yang; G Cole
Journal:  Science       Date:  1996-10-04       Impact factor: 47.728

9.  A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease.

Authors:  S Salloway; R Sperling; S Gilman; N C Fox; K Blennow; M Raskind; M Sabbagh; L S Honig; R Doody; C H van Dyck; R Mulnard; J Barakos; K M Gregg; E Liu; I Lieberburg; D Schenk; R Black; M Grundman
Journal:  Neurology       Date:  2009-11-18       Impact factor: 9.910

10.  Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis.

Authors:  Reisa Sperling; Stephen Salloway; David J Brooks; Donatella Tampieri; Jerome Barakos; Nick C Fox; Murray Raskind; Marwan Sabbagh; Lawrence S Honig; Anton P Porsteinsson; Ivan Lieberburg; H Michael Arrighi; Kristen A Morris; Yuan Lu; Enchi Liu; Keith M Gregg; H Robert Brashear; Gene G Kinney; Ronald Black; Michael Grundman
Journal:  Lancet Neurol       Date:  2012-02-03       Impact factor: 44.182
View more
  13 in total

Review 1.  Tau immunotherapy and imaging.

Authors:  Einar M Sigurdsson
Journal:  Neurodegener Dis       Date:  2013-09-11       Impact factor: 2.977

2.  Amyloid beta immunization worsens iron deposits in the choroid plexus and cerebral microbleeds.

Authors:  Nelly Joseph-Mathurin; Olène Dorieux; Stéphanie G Trouche; Allal Boutajangout; Audrey Kraska; Pascaline Fontès; Jean-Michel Verdier; Einar M Sigurdsson; Nadine Mestre-Francés; Marc Dhenain
Journal:  Neurobiol Aging       Date:  2013-06-22       Impact factor: 4.673

3.  A Novel Small Molecule Modulator of Amyloid Pathology.

Authors:  Mark A Lovell; Bert C Lynn; Shuling Fister; Melissa Bradley-Whitman; M Paul Murphy; Tina L Beckett; Christopher M Norris
Journal:  J Alzheimers Dis       Date:  2016-05-04       Impact factor: 4.472

4.  "Tau immunotherapy: Hopes and hindrances".

Authors:  Koorosh Shahpasand; Alireza Sepehri Shamloo; Seyed Massood Nabavi; Kun Ping Lu; Xiao Zhen Zhou
Journal:  Hum Vaccin Immunother       Date:  2017-12-01       Impact factor: 3.452

Review 5.  "Boomerang Neuropathology" of Late-Onset Alzheimer's Disease is Shrouded in Harmful "BDDS": Breathing, Diet, Drinking, and Sleep During Aging.

Authors:  Mak Adam Daulatzai
Journal:  Neurotox Res       Date:  2015-04-25       Impact factor: 3.911

Review 6.  Common defects of mitochondria and iron in neurodegeneration and diabetes (MIND): a paradigm worth exploring.

Authors:  Matthew Stroh; Russell H Swerdlow; Hao Zhu
Journal:  Biochem Pharmacol       Date:  2013-12-19       Impact factor: 5.858

7.  Alzheimer's disease and immunotherapy.

Authors:  Jennifer Madeo; Marianne Frieri
Journal:  Aging Dis       Date:  2013-03-06       Impact factor: 6.745

8.  Identification of promethazine as an amyloid-binding molecule using a fluorescence high-throughput assay and MALDI imaging mass spectrometry.

Authors:  Richard A McClure; Chad W Chumbley; Michelle L Reyzer; Kevin Wilson; Richard M Caprioli; John C Gore; Wellington Pham
Journal:  Neuroimage Clin       Date:  2013-04-30       Impact factor: 4.881

9.  Calcium Channel Blockers, Progression to Dementia, and Effects on Amyloid Beta Peptide Production.

Authors:  Mark A Lovell; Erin Abner; Richard Kryscio; Liou Xu; Shuling X Fister; Bert C Lynn
Journal:  Oxid Med Cell Longev       Date:  2015-06-28       Impact factor: 6.543

10.  Should interventions to treat or prevent Alzheimer's disease be tested in a population or as targeted treatment of highly selected study participants?

Authors:  Pierre Jean Ousset; Julien Delrieu; Bruno Vellas
Journal:  Alzheimers Res Ther       Date:  2013-12-11       Impact factor: 6.982
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.